BC Extra | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
BioCentury | Mar 14, 2016
Finance

Abingworth's early action

Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile...
BC Week In Review | Sep 1, 2014
Financial News

Median Technologies proposes private placement of units

Median Technologies Inc. (Euronext:ALMDT), Valbonne, France   Business: Diagnostic   Date announced: 2014-08-25   Type: Private placement of units   To be raised: EUR20 million ($26.8 million)   Units: 2.2 million   Price: EUR9 (unit)...
BioCentury | Sep 1, 2014
Finance

Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology....
BC Extra | Aug 26, 2014
Financial News

Median Technologies raising EUR 20 million

Median Technologies Inc. (Euronext:ALMDT) plans to raise about EUR 20 million ($26.8 million) through the sale of 2.2 million units at EUR 9 in a private placement with institutional investors. Each unit comprises a share...
BC Week In Review | Sep 2, 2013
Financial News

Median Technologies completes private placement

Median Technologies Inc. (Euronext:ALMDT), Valbonne, France   Business: Diagnostic   Date completed: 8/19/13   Type: Private placement   Raised: €1.4 million ($1.9 million)   Shares: 132,132   Price: €10.60   Shares after offering: 6 million...
BioCentury | Aug 6, 2012
Finance

Glint of IPO optimism

Aftermarket performance is better for biotech IPOs this year than it was in 2011. Although the basics of what it takes to get an IPO done haven't changed - deals routinely continue to require a discount...
BC Week In Review | Feb 27, 2012
Company News

Median Technologies, Quintiles Transnational Corp. deal

Median, which provides services for image interpretation and management in oncology clinical trials, partnered with the CRO to provide Median's advanced lesion management system (LMS) software applications and associated clinical trial imaging services for early,...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
BC Week In Review | Jul 18, 2011
Company News

Median Technologies, Canon deal

Canon and Median partnered to develop cloud computing-based detection and diagnostic services for neurodegenerative and cardiovascular diseases, as well as cancer. Canon acquired a 16.5% stake in Median for about €8.6 million ($12.2 million). Details...
Items per page:
1 - 10 of 14
BC Extra | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
BioCentury | Mar 14, 2016
Finance

Abingworth's early action

Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile...
BC Week In Review | Sep 1, 2014
Financial News

Median Technologies proposes private placement of units

Median Technologies Inc. (Euronext:ALMDT), Valbonne, France   Business: Diagnostic   Date announced: 2014-08-25   Type: Private placement of units   To be raised: EUR20 million ($26.8 million)   Units: 2.2 million   Price: EUR9 (unit)...
BioCentury | Sep 1, 2014
Finance

Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology....
BC Extra | Aug 26, 2014
Financial News

Median Technologies raising EUR 20 million

Median Technologies Inc. (Euronext:ALMDT) plans to raise about EUR 20 million ($26.8 million) through the sale of 2.2 million units at EUR 9 in a private placement with institutional investors. Each unit comprises a share...
BC Week In Review | Sep 2, 2013
Financial News

Median Technologies completes private placement

Median Technologies Inc. (Euronext:ALMDT), Valbonne, France   Business: Diagnostic   Date completed: 8/19/13   Type: Private placement   Raised: €1.4 million ($1.9 million)   Shares: 132,132   Price: €10.60   Shares after offering: 6 million...
BioCentury | Aug 6, 2012
Finance

Glint of IPO optimism

Aftermarket performance is better for biotech IPOs this year than it was in 2011. Although the basics of what it takes to get an IPO done haven't changed - deals routinely continue to require a discount...
BC Week In Review | Feb 27, 2012
Company News

Median Technologies, Quintiles Transnational Corp. deal

Median, which provides services for image interpretation and management in oncology clinical trials, partnered with the CRO to provide Median's advanced lesion management system (LMS) software applications and associated clinical trial imaging services for early,...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
BC Week In Review | Jul 18, 2011
Company News

Median Technologies, Canon deal

Canon and Median partnered to develop cloud computing-based detection and diagnostic services for neurodegenerative and cardiovascular diseases, as well as cancer. Canon acquired a 16.5% stake in Median for about €8.6 million ($12.2 million). Details...
Items per page:
1 - 10 of 14